Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 59

recruiting
3 977
countries
28
conditions
2 105

1 112 trials match your criteria

Non-small cell lung cancer metastatic

Not recruiting

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib

Prostate cancer

Not recruiting

Study of Florastamin (18F) PET/CT Imaging for Detection of Significant Prostate Cancer in Patients with Elevated PSA Levels and Unclear MRI Results

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(9S,13S)-1-(1-(2-(2-(2-[18F]Fluoroethoxy)Ethoxy)Ethyl)-1H-1,2,3-Triazol-4-Yl)-3,11-Dioxo-2,4,10,12-Tetraazapentadecane-9,13,15-Tricarboxylicacid

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Eosinophilic oesophagitis

Not recruiting

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Giant cell tumour of tendon sheath

Not recruiting

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emactuzumab

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer+2

Not recruiting

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Idiopathic pulmonary fibrosis+1

Not recruiting

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.